Head to Head Survey: Coya Therapeutics (COYA) vs. Its Peers

Coya Therapeutics (NASDAQ:COYA) is one of 985 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Coya Therapeutics to related companies based on the strength of its earnings, risk, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Risk and Volatility

Coya Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Coya Therapeutics’ rivals have a beta of 0.86, meaning that their average share price is 14% less volatile than the S&P 500.

Profitability

This table compares Coya Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	N/A	-42.53%	-37.57%
Coya Therapeutics Competitors	-2,611.00%	-224.76%	-28.17%

Institutional and Insider Ownership

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 9.8% of Coya Therapeutics shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Coya Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coya Therapeutics	$6.00 million	-$7.99 million	-10.73
Coya Therapeutics Competitors	$8.48 billion	$141.08 million	-4.57

Coya Therapeutics’ rivals have higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Coya Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	0	0	2	0	3.00
Coya Therapeutics Competitors	6199	18302	43931	892	2.57

Coya Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 67.26%. As a group, “Pharmaceutical preparations” companies have a potential upside of 78.05%. Given Coya Therapeutics’ rivals higher probable upside, analysts plainly believe Coya Therapeutics has less favorable growth aspects than its rivals.

Summary

Coya Therapeutics rivals beat Coya Therapeutics on 9 of the 13 factors compared.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.